HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 ...

Revenue for Q4 2024 was reported at $17.3 million, an 86.8% year-over-year increase and a 21.3% sequential rise. Regional contributions included EMEA at $11.2 million (65% of total revenue), Americas ...

Langan reaffirmed the company’s five-year capital allocation strategy, aiming for $400 million in revenue and $75 million in free cash flow by FY29. The plan focuses on growing free cash flow per ...